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ABSTRACT The phenobarbitone-responsive minimal
promoter has been shown to lie between nt -179 and nt + 1 in
the 5' (upstream) region of the CYP2BI/B2 gene in rat liver, on
the basis of the drug responsiveness of the sequence linked to
human growth hormone gene as reporter and targeted to liver as
an asialoglycoprotein-DNA complex in vivo. Competition anal-
yses of the nudear protein-DNA complexes formed in gel shift
assays with the positive (nt -69 to -98) and negative (nt -126
to -160) cis elements (PE and NE, respectively) identified within
this region earlier indicate that the same protein may be binding
to both the elements. The protein species purified on PE and NE
affinity columns appear to be identical based on SDS/PAGE
analysis, where it migrates as a protein of 26-28 kDa. Traces of
a high molecularweight protein (94-100 kDa) are also seen in the
preparation obtained after one round of affinity chromatogra-
phy. The purified protein stimulates transcription ofa minine
construct containing the 179 nt on the 5' side of the CYP2BI /B2
gene linked to the I exon in a cell-free system from liver nuclei.
The purified protein can give rise to all the three complexes (I,
II, and III) with the PE, just as the crude nuclear extract, under
appropriate conditions. Manipulations in vitro indicate that the
NE has a significantly higher affnity for the dephosphorylated
form than for the phosphorylated form of the protein. The PE
binds both forms. Phenobarbitone treatment of the animal leads
to a significant increase in the phosphorylation of the 26- to
28-kDa and 94-kDa proteins in nuclear labeling experiments
followed by isolation on a PE affinity column. We propose that
the protein binding predominantly to the NE in the dephospho-
rylated state characterizes the basal level of transcription of the
CYP2BI /B2 gene. Phenobarbitone treatment leads to phosphor-
ylation of the protein, shifting the equilibrium toward binding to
the PE. This can promote interaction with an upstream enhancer
through other proteins such as the 94-kDa protein and leads to
a significant activation of transcription.
Many members of the cytochrome P-450 (CYP) gene super-
family are inducible. However, knowledge regarding the mech-
anisms of induction is restricted to a few members, although
transcriptional activation is a common feature (1, 2). The
mechanism of transcriptional activation of CYPlAl gene,
induced by the prototype chemical 3-methylcholanthrene, has
been studied in detail. It involves interaction of the ligand with
Ah receptor, translocation of the receptor to the nucleus, and
interaction with upstream cis elements (3, 4). However, the
CYP2BI/B2 gene, one of the first mammalian cytochrome
P-450 genes to be identified and cloned, has presented certain
unique features of regulation (5). Although phenobarbitone
(PB) induces this gene (Bi and B2 are 97% homologous and
hence treated as a unit at this stage) essentially through
transcriptional activation, the mechanistic details are not clear.
It has not yet been possible to identify a receptor for PB. The
drug has pleiotropic effects in activating other genes and leads
to hypertrophy of liver. Certain chemicals unrelated to PB in
structure can also activate the CYP2B1/B2 gene. One of the
major problems has been the inability to activate this gene in
cell culture. This poses a limitation in identifying cis-acting
elements and trans-acting factors by using the conventional
transfection assays in cell lines. Recent studies (6) have
indicated conditions for inducing the gene in primary culture,
but details regarding the kinetics of induction in relation to in
vivo responses of the gene and exploitation of the system for
identifying the regulatory features are awaited.
Studies in this laboratory have resorted to approaches based
on transcription of minigene constructs of the CYP2B2 gene in
whole nuclei, run-on and cell-free transcription, DNA-protein
interaction using gel shift assays, footprint analysis, and South-
western blot analysis.
These studies have led to the identification of the near up-
stream region of the CYP2B2 gene (nt + 1 to -179) that contains
the minimal PB-responsive promoter. This region encompasses
the positive (nt -69 to -98) and negative (nt -126 to -160) cis
elements (PE and NE, respectively) (7-9). Reports from two
other laboratories have corroborated the PB responsiveness of
the region within the PE identified in this laboratory (10, 11).
However, Ramsden et al. (12) studying the expression of rat
CYP2B2 gene in transgenic mice have suggested that the PB-
responsive element lies as far as -20 kb from the transcription
start site and that such an element does not seem to be present
within 800 nt upstream of the gene.
In the present study, by using DNA-asialoglycoprotein com-
plexes to target theDNA to the liver after injection into the whole
animal, we show that the near upstream region ofthe CYP2B1/B2
gene (nt + 1 to -179) does encompass the PB-responsive minimal
promoter. The protein factor binding to the PE and NE has been
purified in a functionally active form and its interaction with the
cis elements has been shown to be governed by its phosphoryla-
tion status as influenced by PB administration. A model is
proposed for the modulation of the PB-responsive minimal pro-
moter based on these regulatory interactions at the PE and NE.
MATERIALS AND METHODS
DNA Fragments and Probes. Plasmid pP450e179, the same
as plasmid pP450e4 reported earlier (7), containing 360 nt of
the CYP2B2 gene from nt -179 to +181, was used as the
template in transcription experiments. pOGH plasmid, a
pUC12-based vector containing human growth hormone
structural sequences inserted adjacent to a polylinker (13), was
purchased from Nichols Institute (San Juan Capistrano, CA).
pRSV-CAT (14) was used as an internal control in in vivo
experiments. The plasmid containing the promoter region of
phosphoenolpyruvate carboxykinase (Pepck) gene of rat liver
(nt -490 to +73) (15) was obtained from R. W. Hanson.
Abbreviations: PB, phenobarbitone; PE, positive cis element; NE,
negative cis element; CAT, chloramphenicol acetyltransferase.
9628
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement" in
accordance with 18 U.S.C. §1734 solely to indicate this fact.
Proc. Natl. Acad. Sci. USA 92 (1995) 9629
The f6llowing oligonucleotides were synthesized by using Gene
Assembler plus (Pharmacia): PE, 5'-GAGGAGTGAATAGC-
CAAAGCAGGAGGCGTG-3' (nt -98 to -69 of the CYP2B2
gene and its complementary sequence); NE, 5'-TTTTGTCCT-
GTGTATC(TGTTTCGTGGTGTCCTTG-3' (nt -160 to -127
of the CYP2B2 gene and its complementary sequence).
DNA Targeting and Expression in Liver. The DNA fragment
containing 179 nt of the upstream region of the CYP2B2 gene was
released with BamHI-Nco I from pP450e179 DNA and then
ligated intoBamHl-digested pOGH DNA, a pUC12-based vector
containing human growth hormone structural sequence inserted
adjacent to a polylinker (13). After ligating the BamHI ends, the
Nco I end of the insert andBamHI end of the vector were filled-in
and blunt-end-ligated. The plasmid is referred to as pP450GH
and the DNA (50 ,g) was complexed with a polylysine-
asialoglycoprotein conjugate as described (16). The DNA-
protein complex was injected intravenously in two doses (each of
50 jtg/0.5 ml) at 24-hr interval into rats (75-80 g). In some
experiments, pP450GH (50 ,ug) and pRSV-CAT (50 ,ug) were
injected together as asialoglycoprotein complexes. PB (8 mg/100
g) was injected 1 hr after each injection of conjugate. The animals
were killed 12 hr after the second injection of PB, and RNA was
isolated from total liver and analyzed by slot blot analysis with the
growth hormone DNA probe prepared from pOGH DNA.
Animals receiving pOGH DNA or saline with or without PB
treatment served as controls.
Purification of the Transcription Factor. The PE and NE
(nt -69 to -98 and nt -126 to -160, respectively) were multi-
merized by self ligation. Multimers with -15 repeats (200 jig)
were covalently linked to 10 ml of CNBr-activated Sepharose
2B as described (17). The coupling efficiency was "70%.
Nuclei were obtained from rat liver by using citric acid
homogenization (18). The nuclei were suspended in 10 mM
Tris-HCl, pH 7.5/50 mM NaCl/0.5 mM MgCl2/50 mM su-
crose/10 mM 2-mercaptoethanol. NaCl from a stock of 4 M
was added drop by drop to 0.45 M, and the suspension was left
on ice for 30 min with intermittent vortex mixing. The sus-
pension was centrifuged in a SS34 (Sorvall) rotor at 12,000 rpm
for 10 min and the supernatant was subjected to 80%
(NH4)2SO4 saturation. The precipitate was dissolved in 10 mM
Tris-HCl, pH 7.6/1 mM EDTA/50 mM NaCl/10 mM 2-mer-
captoethanol in 15% (vol/vol) glycerol and dialyzed against
the same buffer for 4 hr with one change. The preparation was
passed through a heparin-agarose column, and 0.3 M, 0.5 M,
and 0.7 M NaCl eluates were collected on the basis of complex
formation in gel mobility shift assays.
The oligo affinity column (1 ml) was equilibrated with Z
buffer (25 mM Hepes, pH 7.6/12.5 mM MgCl2/1 mM dithio-
threitol/20% glycerol) containing 0.1 M KCl. The nuclear
extract (directly or after heparin-agarose fractionation) was
dialyzed against Z buffer containing 0.1 M KCl, combined with
sonicated salmon sperm DNA (440 ,ug for 10 mg of nuclear
protein), and allowed to stand for 10 min. The protein-DNA
mixture was passed through the affinity column (15 ml/hr) and
washed with 15 ml of the same buffer. Then 1.2 ml of Z buffer
containing 1 M KCl was added to the column that was closed,
and the resin was stirred and allowed to stand for 10 min. The
protein was then eluted. For further purification, the eluate
was diluted to 0.1 M KCl with Z buffer and mixed with
competitor DNA, and column procedure was repeated. The
eluted protein was concentrated by using a Centricon unit,
separated into aliquots and stored at -70°C.
Gel Mobility Shift Assay. Nuclear extract (1-3 ,ug of protein)
or the purified preparation was used for binding with end- or
body-labeled PEs or NEs in the presence of poly(dI-dC), and
samples were analyzed on low-ionic-strength 9% polyacryl-
amide gels as described (8). The effect of phosphorylation
status of the purified factor on binding was examined by
treating the protein preparation with calf intestinal alkaline
phosphatase (0.6 unit) or protein kinase (catalytic subunit of
protein kinase A from bovine heart muscle, 1 unit).
Cell-Free Transcription. Transcription extracts were prepared
from control and PB-treated nuclei as described above. The
extracts after 80% (NH4)2SO4 precipitation and dialysis were
used. The 20-pl reaction mixtures contained supercoiled DNA
template (50 p,g/ml) (pP450e179 or Pepek), transcription extract
(50-100 Mg/ml), 25 mM Hepes-KOH (pH 7.0), 50 mM KCI, 6
mM MgCl2, 0.6 mM ATP, 0.6 mM GTP, 0.6 mM CTP, and 0.6
mM UTP, 12% glycerol, and 30 units of RNase inhibitor (RNa-
sin). The transcription extracts prepared by this method were
found to be very active, and 1-2 ,ug of protein per 20-IlI reaction
mixture was found to be adequate. Purified factor was incubated
at 30°C for 45 min. The transcripts were isolated after RNase-free
DNase and proteinase K treatments followed by phenol/CHCl3
extraction and ethanol precipitation. The transcripts were quan-
tified by RNase protection (19). Labeled RNA probes for the
exonic sequences present in pP450e179 andPepckwere generated
by using T7RNA polymerase and [a-32P]UTP in apGEM vector.
The labeled RNA was hybridized with the cell-free transcripts,
digested with RNases A and Ti, analyzed on polyacrylamide/
urea gels (8% gels), and autoradiographed.
Labeling of Nuclear Proteins with [y-32P]ATP. Nuclei (400
,ug of DNA) isolated from uninduced or PB-induced rat liver
were incubated with [y-32P]ATP (50 ,uCi; 1 Ci = 37 GBq) and
other components used in run-on transcription (7, 8) in 200 ,ul
at 30'C for 45 min. At the end of the incubation, the nuclei
were pelleted and proteins were extracted with 0.45 M NaCl.
Okadaic acid (2 ,uM) was included in the incubation and
extraction buffers. The extracts (equal amounts of protein)
were loaded onto the PE affinity column as described above.
The column was thoroughly washed and then material was
eluted with Z buffer containing 1 M KCI. After dilution and
the addition of bovine serum albumin (50 ,ug), the protein was
precipitated with 7% (wt/vol) trichloroacetic acid. The pellet
was suspended in SDS buffer, dissociated, analyzed by SDS/
PAGE (8% gels), and autoradiographed.
RESULTS
In view of the difficulty of inducing CYP2B1/B2 gene tran-
scription in cell culture and the consequent inadequacy of the
system to study the regulatoryDNA elements by using reporter
gene assays after cell transfection, we targeted the DNA to the
liver in vivo and studied its expression. For this purpose, the
179-nt fragment of the 5' upstream region of CYP2B2 gene was
inserted into the polylinker region of the plasmid pOGH
containing growth hormone structural gene sequences as
reporter. This plasmid, pP450GH, was injected as an asialo-
glycoprotein-polylysine complex that is directed to liver, since
liver has an asialoglycoprotein receptor (16). This approach
has been used to target and express genes in liver (20). The
results presented in Fig. LA indicate that expression of the
reporter gene (namely, growth hormone mRNA) can be
detected to a significant extent only in animals receiving
pP450GH and PB, but not in any of the controls employed. To
account for variations in DNA uptake between animals,
experiments have also been conducted by injecting the two
plasmid DNAs [namely, pP450GH (50 ,g) and pRSV-CAT (50jug)] together and assessing the expression of growth hormone
and chloramphenicol acetyltransferase (CAT) mRNAs under
these conditions. The results presented in Fig. 1B clearly
indicate that PB treatment elicits a significant increase in
growth hormone mRNA. CAT mRNA expression is seen in
animals not receiving PB, and the drug treatment may slightly
decrease expression. These results establish that the 179-nt
sequence 5' upstream of the CYP2BJI/B2 gene represents a
minimal PB responsive promoter under in vivo conditions.
The next step was to decipher the regulatory interactions at
the PEs (nt -69 to -98) and NEs (nt -127 to -160). The crude
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FIG. 1. Slot blot analysis of growth hormone or CAT mRNA as
reporter in rat liver targeted with pP450e179 or pRSV-CAT DNA. (A)
Rows 1-3 show signals obtained with 30, 20, and 10 ,ug of total RNA,
respectively. The treatments were as follows. Lanes: 1, control (saline);
2, PB; 3, pOGH (plasmid DNA without promoter), 4, pOGH + PB;
5, pP450GH (plasmid DNA with 179 nt upstream); 6, pP450GH + PB.
(B) Row 1 shows signal obtained with 20 ,ug of total RNA by using
growth hormone or CAT probes. Row 2 shows signal after RNase
treatment. The experiments have been repeated four times and the
data presented are those obtained in a typical experiment. The
expression of growth hormone mRNA in response to PB (lanes 2)
ranges from 5- to 10-fold in various experiments over the signals
obtained with saline-injected controls or nontransfected animals
(lanes 1). Livers from two animals were pooled from each treatment
group.
nuclear extract gives three complexes (I, II, and III) with the
labeled PE. Complex III is predominantly seen at higher protein
concentrations (Fig. 2). The complexes are specific and are not
competed by excess of nonradioactive heterologous oligonucle-
otides such as SP1 and AP1. Interestingly, the complexes formed
with the labeled PE are competed by an excess of PEs or NEs.
Attempts were made to purify the protein factors binding to the
PEs and NEs. For this purpose, crude nuclear extracts were
passed through a heparin-Sepharose column and the various salt
eluates were assessed for binding to the PE in gel shift assays. The
0.3 M-0.5 M NaCl eluate gave significant binding, and this
fraction was processed on the oligo affinity column prepared with
multimerized PE. The affinity-purified preparation shows a sharp
band at 26-28 kDa (sometimes a doublet) and very faint bands
in the 90-kDa region in SDS/PAGE gels (Fig. 3). Subsequent
experiments carried out with the multimerized NE have given a
similar protein preparation (data not presented).
The affinity-purified preparation essentially gives rise to
complex III with the PE, although faint bands corresponding
to complexes I and II can also be seen. The binding of the
purified preparation from the PE affinity column to the
labeled PE is competed by a 10-fold excess of nonradioactive
P M kDa
-94
*ED-67 FI. 3. Purification of protein fac-
tor on PE affinity column. The exper-
imental details are given in the text.
Briefly, 10 mg of crude nuclear extract
-30 was loaded on the heparin-agarose col-
umn and the 0.3-0.5 M NaCl eluate
was dialyzed and loaded on an oligo
* -20 affinity column; 25% of the 1 M salt
eluate was analyzed by SDS/PAGE on
14 8% gels and stained with silver. Lanes:
*
14 P, purified protein; M, marker pro-
teins.
PEs as well as NEs, but not by SP1 at concentrations as high
as a 50-fold excess of the labeled oligonucleotide (Fig. 4A). The
purified preparation binds to the labeled PEs and NEs and in
fact binds significantly more to the NE (Fig. 4B).
To examine whether modulation of the phosphorylation
status of the purified preparation influences its binding to the
cis elements, the preparations were treated with calf intestinal
alkaline phosphatase or protein kinase and then gel shift assays
were carried out. It is of interest to note that phosphatase and
kinase treatment of the preparation enhance binding to the
PE, the effect of kinase being more pronounced than phos-
phatase (Fig. 5A). On the other hand, kinase treatment
decreases binding to the NE, whereas phosphatase treatment
strikingly increases binding (Fig. 5B). Kinase treatment stim-
ulates binding to the PE at higher concentrations of the
purified protein when all three complexes are seen, the effect
being predominantly seen with complex III (Fig. SC).
To examine whether PB treatment actually leads to a change
in the phosphorylation status of the factor, nuclei were isolated
from uninduced and PB-induced rats. The nuclei were incu-
bated with [y-32P]ATP, and the labeled protein extract was
passed through the PE affinity column. Equal amounts of
nuclei and extracted proteins were processed. The results
presented in Fig. 6B clearly indicate that PB treatment leads to
enhanced phosphorylation of the 26- to 28-kDa protein. In
addition, enhanced phosphorylation of the 94-kDa protein is
also seen. However, when the purified protein preparation is
phosphorylated in vitro with protein kinase and [y-32P]ATP,
the doublet is strikingly labeled (Fig. 6A).
The functional properties of the oligo affinity-purified prep-
arations from PB-induced and uninduced rat liver nuclei
(heparin-Sepharose step omitted) were assayed by using cell-
free transcription with pP450e179 DNA as the template. In
general, the transcription extract prepared from induced nu-
A 1 2 3 4 B (1 1 2 3 4 5 6
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FIG. 2. Gel shift assays with labeled PE and crude nuclear extract.
(A) Effect of protein concentration on the intensity of the complexes
obtained. Lanes: 1, 2.25 jig; 2, 2.0 ug; 3, 1.75 ,g; 4, 1.5 jig of protein.(B) Specific nature of the complexes formed. Amount of protein used
was 1 ,ug. Nonradioactive PE and NE were used at 10-fold excess in
competition experiments. The other nucleotides (SP1, AP1, and
GRE) were used at 25-fold excess. Lanes: 0, no chase; 1, PE; 2, NE;
3, SP1; 4, AP1; 5, GRE; 6, GRE + AP1. Lanes 1-6 represent chase
experiments with excess of unlabeled oligonucleotides. Positions of
complexes I-III are indicated.
A 1 2 3 4 5 B
1, *._I
low
FIG. 4. Gel shift analysis with the purified factor. (A) The factor
purified from uninduced nuclear extracts on PE affinity column was
used to study binding with labeled PE. Competition carried out with
a 10-fold excess of PEs or NEs and a 50-fold excess of SP1. Lanes: 1,
purified factor; 2, purified factor + PE; 3, purified factor + NE; 4,
purified factor + SP1; 5, no addition. (B) Purified factor binding to PE
and NE under identical conditions. Lanes 1 and 2 are duplicates with
4 ,ul of purified protein fraction binding to PEs. Lanes 3 and 4 show
binding to NE labeled to same specific activity as the PE with 4 A.l and
1 ,ul of the purified protein fraction, respectively.
A 1 2 3 4 5 6
3
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FIG. 5. (A) Effect of kinase and phosphatase treatment of the
purified factor (4 ,1) in gel shift assays with PEs. Lanes: 1 and 4,
purified factor; 2, purified factor + phosphatase; 3, no additions; 5,
purified factor + kinase. (B) NE and 1 ,ul of purified protein fraction.
Lanes: 1 and 3, purified factor; 2, purified factor + kinase; 4, purified
factor + phosphatase; 5, no addition. (C) PE and 12 ,ul of purified
protein fraction. Lanes: 1, factor; 2, factor + kinase.
clei transcribes the pP450e179 DNA template used more
efficiently than the uninduced extract. In the experiment
presented, the PB-transcription extract is 5.2-fold more active
than the control extract. The difference ranges between 2- and
7-fold with different batches of uninduced and induced cell-
free extracts. The factor purified from both uninduced and
induced nuclear extracts is effective in stimulating transcrip-
tion, although the preparation from the induced extract is
generally more effective. In the experiment presented, the
factor from induced extract stimulates transcription in the
cell-free transcription extract prepared from uninduced nuclei
by 11.0-fold compared to the stimulation of 6.2-fold obtained
with the factor purified from uninduced nuclear extract.
Finally, the stimulatory effect of the purified factor is more
with the uninduced cell-free transcription extract than that
obtained with the preparation from PB-induced nuclei. In the
experiment presented, the purified factor from uninduced and
induced nuclear extracts stimulates transcription in induced
extracts by 1.2- and 1.3-fold, respectively; the corresponding
values for the uninduced transcription extracts are 6.2- and
11.0-fold, respectively. As stated above, the basal value from
the PB-induced transcription extract is 5.2-fold more than that
of the uninduced extract (Fig. 7A). To examine the specificity
of the effects of the factor, the results obtained with pP450e179
DNA and Pepck DNA have been compared. Although the
purified factor stimulates the transcription of pP450e179
DNA, it inhibits transcription of Pepck DNA (Fig. 7 B and C).
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FIG. 6. Phosphorylation of protein factor in nuclei in vitro. (A)
Purified factor preparation phosphorylated in vitro with kinase and
[y-32P]ATP. (B) Control nuclei (lane 1) and PB nuclei (lane 2)
phosphorylated with [y-32P]ATP and then factor purified on PE
affinity column. Equal amounts of nuclei and extracted proteins were
processed on the column. The protein preparations were analyzed by
SDS/PAGE on 8% gels and autoradiographed.
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FIG. 7. (A) Effect of purified factor on cell-free transcription of
pP450e179 DNA. Lanes and bars: 1, control cell-free transcription
extract; 2, control extract + factor purified from uninduced nuclear
extracts; 3, control extract + factor purified from PB-induced nuclear
extracts; 4, cell-free transcription extract from PB-induced nuclei; 5,
PB extract + factor purified from uninduced nuclear extracts; 6, PB
extract + factor purified from PB-induced nuclear extracts. Approx-
imately 3 ng of purified protein obtained after a single-step oligo-
nucleotide affinity column was used. (B) pP450e179 DNA. Lanes: 1,
control transcription extract; 2, control extract + purified protein
fraction obtained after heparin agarose and oligonucleotide affinity
column (2 ,ul). (C) Pepck DNA. Lanes: 1, control transcription extract;
2, control extract + purified protein fraction (2 ,lI).
DISCUSSION
In vitro studies in this laboratory (7, 8) have led to the conclusion
that the sequence of nt -179 to nt + 1 of the 5' upstream region
of the CYP2B2 gene harbors the minimal PB-responsive pro-
moter. The presence of a PB-responsive element in the region
from nt -69 to nt -98 has been corroborated by two other
laboratories (10, 11). However, Ramsden et al. (12), on the basis
of experiments with transgenic mice using full-length rat CYP2B2
gene, concluded that the PB-responsive element lies as far as -20
kb and is not detectable within 800 nt of the 5' upstream
sequence. Studies with direct gene injection experiments in vivo
presented herein have clearly revealed that there is a PB-
responsive element within 179 nt of the 5' upstream sequence of
the CYP2B2 gene. Further studies reveal that there are NEs
upstream at nt -365 and downstream at nt -800 (unpublished
data). This could be one reason why PB responsiveness is not
observed with the entire 800-nt upstream region in transgenic
experiments. In addition, a subset of the PEs identified in this
laboratory (7, 8) has been referred to as a Barbie box, the PB
responsive element, and identified in Bacilus megaterium (10),
Streptomycesgriseolus (21), and rat a-acid glycoprotein gene (22).
Recently, Liang et al. (23) have also suggested that the results of
Ramsden etal. (12) with transgenic mice may be open to alternate
interpretations. The enhancer function of the -20-kb region is
nevertheless a valid concept.
It has been possible to purify the factor(s) binding to the
cis-acting elements in the near upstream of the CYP2B2 gene.
The factor is obtained as a protein of 26-28 kDa (sometimes
as doublet) and is functionally active. The preparation purified
on the PE affinity column stimulates cell-free transcription of
pP450e179 DNA. Different batches of cell-free extracts pre-
pared from PB-treated rat liver nuclei are 2- to 7-fold more
active than control nuclear extracts in the transcription of this
DNA. The purified factor from PB-treated rats in general is
more effective than the preparation from control rats. Again,
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the stimulation obtained with control cell-free transcription
extracts is more than that obtained with PB cell-free transcrip-
tion extract, the basal level being higher in the latter case.
However, strict comparisons become difficult, since the pro-
tein factor yield is very low and exact quantitation of its protein
content is not feasible. In addition, preliminary studies reveal
that the factor may get partially dephosphorylated during bulk
purification due to cellular phosphatases and the factor may
also undergo phosphorylation during incubation under con-
ditions of cell-free transcription. This is possibly the reason
why purified preparations from uninduced and induced states
are effective, although the preparation from induced animals
is significantly more active than that from control animals in
transcription extracts prepared from uninduced rats.
It is interesting to note that the same factor (26-28 kDa)
in terms of mobility is purified from both PE and NE affinity
columns. The factor binding to the labeled PE is competed
by either the PE or NE in excess. Again, the factor purified
from the PE affinity column binds to labeled PE and NE
oligonucleotides. All these results indicate that the protein
species binding to the PE or NE is the same. However,
definitive answers would require immunological and struc-
tural identity.
Gel shift analysis with the purified factor after phosphatase
and kinase treatments indicates that while the PE can bind
both the phosphorylated and dephosphorylated states; the NE
shows a preference for the dephosphorylated state. In fact, the
factor purified from uninduced rats shows a significantly
higher binding to the NE than to the PE. This laboratory has
demonstrated (8, 9) that the uninduced nuclear extract binds
more to the NE than does the PB-induced extract, and the
reverse was found with the PE in gel shift analysis. These
results and the fact that PB treatment leads to enhanced
phosphorylation of the 26- to 28-kDa and 94-kDa proteins in
nuclei lead us to the following proposition (Fig. 8). Under
uninduced conditions, the factor (26-28 kDa) is predomi-
nantly in the dephosphorylated state and binds to the NE,
keeping the gene in a repressed state, permitting only basal
transcription. This interaction may involve additional pro-
tein(s), but interaction with upstream enhancer is precluded.
Basal
PE
Induced
NE
PE
FIG. 8. Model for the transcriptional regulation of CYP2BI/B2
gene. The basal state (+) depicts predominant interaction at the
negative site (NE) through the dephosphorylated protein factor (-P)
making contact with the initiation complex (IC), perhaps involving at
least one other protein (X). Interaction with enhancer is precluded.
The PB-induced state (+ + +) depicts predominant interaction of the
phosphorylated protein factor (+P) with the PE, also interacting with
the upstream enhancer element recognizing protein (E), perhaps
involving the 94-kDa (Y) protein as well. The PE-enhancer element
interaction with the initiation complex leads to the induced state of
transcription. The arrow indicates the direction of transcription.
PB treatment leads to enhanced phosphorylation of the factor
(26-28 kDa) shifting the equilibrium toward binding to the PE,
perhaps involving additional proteins such as the 94-kDa
protein that may also get phosphorylated. It is interesting to
note that earlier studies from this laboratory (7, 24) identified
the 94-kDa protein in nuclear extracts binding to the entire
labeled 179-nt 5' upstream sequence by Southwestern analysis.
Thus, the 94-kDa protein may interact with the 26- to 28-kDa
protein but is significantly lost during purification of the factor
(26-28 kDa), although it is detected as a faint band in
preparations obtained after a single round of affinity chroma-
tography. As reported in this study, the purified factor in low
concentrations generates essentially complex III with the PE in
gel shift assays. At 5- to 10-fold higher protein concentrations,
complexes 1-111 are generated and this may require the
participation of the 94-kDa protein, the latter being present in
less than stoichiometric concentrations in the purified prepa-
ration. This protein-protein interaction can promote interac-
tion with the far upstream enhancer element, permitting
striking activation of transcription by the inducer.
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